Pharmacovigilance (PV) is defined according to WHO as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. WHO established its Programme for International Drug Monitoring in response to the thalidomide disaster detected in 1961. Together with the WHO Collaborating Centre for International Drug Monitoring, Uppsala, WHO promotes PV at the country level. At the end of 2010, 134 countries were part of the WHO PV Programme. The aims of PV are to enhance patient care and patient safety in relation to the use of medicines; and to support public health programmes by providing reliable, balanced information for the effective assessment of the risk-benefit profile of medicines.

Welcome to the on-line reporting site for the ADR Scheme

Report a side effect with the Adverse Drug Reaction (ADR) Scheme

The MUP Company encourages you to report any suspected side effects (also known as adverse drug reactions) that you suspect might be associated with a medicine by clicking "Adverse Drug Reaction On-line Reporting Scheme" The yellow box on the right side.

Healthcare professionals and patients themselves can report side effects using the Adverse Drug Reaction On-line Reporting Scheme, which is run by the MUP Pharmacovigilance department.

Comprehensive reporting and monitoring should lead to the safer use of medicines, while also helping to improve public health.

Important information about side effects

All medicines can cause side effects. Some may not yet be known so that's why it's important for people to report to the "Adverse Drug Reaction On-line Reporting Scheme".   In General, many side effects are mild, but some can be serious and even life-threatening. Others appear after taking a medicine for a long time or even after stopping a medicine.

It is important for people to report as these are used to identify side effects and other problems which might not have been known about before.     If a new side effect is found, the MUP Pharmacovigilance department referring to the EPVC will review the way that the medicine can be used, and the warnings that are given to people taking it to minimise risk and maximise benefit to the patient. Further information can be found under our FAQ section.

Please note we cannot provide medical advice. If you are worried about a symptom you think may be a side effect:

  1. Check the patient information leaflet supplied with the medicine. This lists the known side effects and advises you what to do.
  2. Talk to your doctor or pharmacist.


What we need to Reach:

1- Improve patient care and safety
2- Improve public health
3- Detect problems related to the use of medicines and communicate the finding in timely manner
4- To contribute to the assessment of the risk-benefit profile of the medicine, thus encouraging safer and more effective use of medicines
5- Promote understanding and education in Pharmacovigilance and its effective communication to the public.


Importance of ADR Cards:

1- Early detection of ADRs.
2- Detection of increased frequency of ADRs
3- Identification of predictors and possible mechanisms underlying ADRs
4-Quantitative estimation of Risk/ Benefit profiles of drugs and dissemination of information needed to improve drug prescribing and regulation
5- Prevention of preventable ADRs
6- Encouraging rational and safe use of drugs


Related Links

The Egyptian Drug Authority (EDA)
The Uppsala Monitoring Center (UMC)
WHO Pharmacovigilance Toolkit
Anti-Poison and pharmacovigilance Center of Morocco 


Medical Union Pharmaceuticals newsletter

Subscribe with your e-mail address to stay up-to-date. We will send you all new MUP news, product launches, Pharmacovigilance cases and our activity to be up-to-date

Go to top